# Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

> **NCT06041620** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 2 (estimated)

## Conditions studied

- Thalassemia, Beta
- Thalassemia Major

## Interventions

- **BIOLOGICAL:** VGB-Ex01

## Key facts

- **NCT ID:** NCT06041620
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2023-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041620, "Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06041620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*